Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

9
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
9
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

34
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
34
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

9.2K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
9.2K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

535
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
535

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone abuse in Brazil: a growing public health challenge.

Clinics (Sao Paulo, Brazil)·2026
Same author

Is serum neurofilament light chain accurate enough to guide multiple sclerosis care? Diagnostic performance and optimal cutoff in a systematic review and meta-analysis.

Multiple sclerosis and related disorders·2026
Same author

Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort.

Clinical neurology and neurosurgery·2026
Same author

Age trumps metabolism: No independent association between lipids, statins, and prostate enlargement in a metabolically controlled cohort.

Clinics (Sao Paulo, Brazil)·2026
Same author

Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.

Arquivos de neuro-psiquiatria·2026
Same author

Partnered sexual activity and satisfaction in women with spinal cord disease: influence of urinary incontinence and other predictors.

Spinal cord·2026

Related Experiment Video

Updated: Apr 24, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Voiding dysfunction in patients with neuromyelitis optica spectrum disorders.

Fabricio Leite de Carvalho1, Cristiano Mendes Gomes1, Samira L Apostolos-Pereira2

  • 1Division of Urology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.

Neurourology and Urodynamics
|September 13, 2014
PubMed
Summary

Patients with neuromyelitis optica spectrum disorder (NMO-SD) frequently experience lower urinary tract symptoms (LUTS) and voiding dysfunction. Detrusor-sphincter dyssynergia (DSD) and detrusor overactivity (DO) are common urodynamic findings, worsening with disease severity.

Keywords:
bladder dysfunctiondemyelinating diseaseslower uinary tract symptomsneuromyelitis opticaurodynamics

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

13.4K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

11.7K

Related Experiment Videos

Last Updated: Apr 24, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

13.4K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

11.7K

Area of Science:

  • Neurology
  • Urology
  • Neuroimmunology

Background:

  • Neuromyelitis optica spectrum disorders (NMO-SD) are autoimmune conditions affecting the central nervous system.
  • Lower urinary tract symptoms (LUTS) and voiding dysfunction are common but understudied in NMO-SD.
  • Understanding these symptoms is crucial for patient management and quality of life.

Purpose of the Study:

  • To assess the prevalence and characteristics of LUTS in patients with NMO-SD.
  • To identify urodynamic findings associated with NMO-SD.
  • To explore the relationship between neurological impairment and lower urinary tract dysfunction.

Main Methods:

  • Prospective evaluation of 30 patients diagnosed with NMO-SD.
  • Neurological assessment using the Expanded Disability Status Scale (EDSS).
  • LUTS assessment via Overactive Bladder questionnaire (OAB-V8) and International Prostate Symptom Score (I-PSS), alongside videourodynamics.

Main Results:

  • Most NMO-SD patients reported LUTS and voiding dysfunction.
  • Detrusor-sphincter dyssynergia (DSD) and detrusor overactivity (DO) were the most frequent urodynamic findings.
  • Increased voiding dysfunction correlated significantly with higher EDSS scores, indicating a link between neurological severity and bladder dysfunction.

Conclusions:

  • LUTS and voiding dysfunction are prevalent in NMO-SD patients.
  • DSD and DO are key urodynamic abnormalities in this population.
  • Neurological disease severity is a significant predictor of voiding dysfunction and DSD in NMO-SD.